30 closest matches · ranked by relevance
Hematologic Malignancies · Bone Marrow Transplant Rejection
Primary: The Proportion of Patients Who Develop Full Donor T Cell Chimerism at Day 30 — 44.9 percentage of participants
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Chronic Lymphocytic Leukemia
Primary: Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System — 43; 4 participants
Multiple Myeloma
Primary: Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS) — 0.31 Proportion of participants PFS
Dyskeratosis Congenita · Aplastic Anemia
Primary: Neutrophil Engraftment — 15; 20 Participants
Hematologic Neoplasms
Primary: Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for…
Diamond-Blackfan Anemia · Kostmann's Neutropenia · Shwachman-Diamond Syndrome
Primary: Number of Patients Alive (Survival) at 2 Years — 6 Participants
Myeloproliferative Disorders · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants Who Experienced Transplant Related Mortality — 5; 4 Participants
Mucopolysaccharidosis I · Mucopolysaccharidosis VI · Mannosidosis
Primary: Mean Percentage of Donor Cells in Study Population (Chimerism). — 85.8; 73.2; 84.6; 81.1 Percentage
Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA) · Severe Aplastic Anemia (SAA)
Primary: Number of Participants Who Engrafted by Day 42 — 30 Participants
Inherited Immune Deficiencies
Primary: Stem Cell Transplant Engraftment — 7; 31; 3; 0 Participants
Lymphoma · Disorder Related to Bone Marrow Transplantation
Primary: Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA) — 19; 6; 0; 0 participants
Hodgkin's Disease
Primary: Transplant Related Mortality Rate — 1; 6 Participants
Dyskeratosis Congenita · Aplastic Anemia
Primary: Incidence of Neutrophil Engraftment — 100; 100; 96; 100 Percentage of participants
CML (Chronic Myelogenous Leukemia) · CLL (Chronic Lymphocytic Leukemia) · AML (Acute Myelogenous Leukemia)
Primary: To Determine if Selective T Cell Depletion Using the Photodepletion Procedure Can Substantially Reduce the Rate of Severe Acute GVHD (Grade III/IV) After Matched Sibling…
Sickle Cell Disease
Primary: Number of Participants With Graft Failure — 3 Participants
Myelodysplastic Syndrome · Hodgkin's Lymphoma · Non-Hodgkin's Disease
Primary: Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD) — 42; 38 percentage of participants
Anemia, Aplastic · Amegakaryocytic Thrombocytopenia · Diamond-Blackfan Anemia
Primary: Treatment Failures
Sickle Cell Disease · Thalassemia · Severe Congenital Neutropenia
Primary: Number of Patients Who Experienced Grade 3-5 Treatment Related Toxicity — 0; 0; 2 Participants
Hematologic Malignancy
Primary: Number of Participants That Experience One Year Relapse Free Survival After Undergoing Hematopoietic Stem Cell Transplant (HSCT) — 5 Participants
Lymphoma, Non-Hodgkin
Primary: Progression-Free Survival (PFS) — 73 percentage of participants
Adrenoleukodystrophy · Metachromatic Leukodystrophy · Globoid Cell Leukodystrophy
Primary: Overall Survival — 120; 92; 81 Participants
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute · Burkitt Lymphoma
Primary: Overall Survival at 180 Days From the Time of Transplant — 73.5; 54.0 percentage of participants
Allogeneic Stem Cell Transplant · Leukemia · Non-Hodgkins
Primary: Overall Survival of Transplant Patients — 727.5 Days
Systemic Scleroderma · Severe Systemic Sclerosis
Primary: Event-free Survival (EFS) — 1 Participants
Leukemia
Primary: Median Time to Engraftment of Neutrophils — 11; 11 days
Systemic Scleroderma
Primary: EFS of Patients Undergoing Transplant — 15 participants
Hemophagocytic Lymphohistiocytosis · X-Linked Lymphoproliferative Disorders · Chediak-Higashi Syndrome
Primary: Number of Subjects With Mixed Chimerism — 3; 8; 4 participants
Hematopoietic/Lymphoid Cancer
Primary: Count of Participants That Experience 1 Year Relapse Free Survival After Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Using the Thomas Jefferson University…
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Day 100 TRM — 4 Participants
Leukemia · Myeloproliferative Disorders · Myelodysplastic-Myeloproliferative Diseases
Primary: Two-year Overall Survival — 46; 51 percentage of patients